CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 686 target
Drug / intervention
Dexmedetomidine nasal spraydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06619912
NCT06619912Phase 3RecruitingOn TrackUpdated 11mo ago
CompareCT.gov

Dexmedetomidine in Reducing Postoperative Delirium in Cardiac Surgery Patients：a Single-center, Double- Blind, Controlled Trial

Xijing Hospital·interventional·Posted Oct 1, 2024·Updated Jul 22, 2025

In Brief

A Phase 3 clinical trial evaluating Dexmedetomidine nasal spray for Postoperative Delirium and Preoperative Sleep Disorder. Currently recruiting, targeting 686 participants across 1 site.

Detailed Summary

Delirium is a common consequence of cardiac surgery and associates with poor outcomes. Multiple causes can trigger delirium occurence, and it has been hypothesised that sleep disturbances can be one of them. Dexmedetomidine may be effective in reducing delirium. The aim of this study was to demonstrate preoperative dexmedetomidine nasal spray in cardiac surgery patients can reduce postoperative delirium by improving preoperative sleep.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Delirium, Preoperative Sleep Disorder
CountriesChina
Collaborators--

Timeline

Phase 3Recruiting
202520262027
First PostedOct 1, 2024
Enrollment StartMar 3, 2025
Primary CompletionOct 31, 2026
Study CompletionMar 30, 2027
TodayJul 1, 2026
Enrollment to primary: 1.7 yearsPosted 1.8 years agoPrimary completion in 4 months

Interventions

Dexmedetomidine nasal spraydrug

Participants will be randomised to receive either dexmedetomidine or saline nasal spray (1.5ug/kg, ideal body weight) at the night before surgery and 30 minutes before induction.